Although there is a universal acknowledgement that health inequalities need to be addressed, the question is “How?” Precision’s Jason Shafrin and Meena Venkatachalam explain that simply incentivizing research and development efforts to create new drugs in therapeutic areas that disproportionately impact minorities won’t resolve the problem. Rather, we need to change traditional value assessment frameworks to move towards equity in health outcomes.
Read the full article here!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
